Greystone Research Associates is pleased to announce the publication of a new
market study. Transdermal Hormone Replacement: Products, Players, Markets
and Forecasts is a comprehensive evaluation and analysis of the
technology, products and participants providing the driving force behind this
evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug
developers, device packaging designers, healthcare marketers, and supply chain
participants with a detailed understanding of the products, markets and
commercial opportunities for therapeutic hormones administered transdermally.
Provider organization business managers, healthcare administrators and
investors will also benefit from this study.
The Evolving Landscape for Hormone Replacement
As life expectancy in the developed world increases and populations age, the
incidence and associated morbidity of decreasing hormone levels have come to
the forefront as a quality-of-life issue for patients and their families. For
the past two decades, the healthcare industry has responded to this clinical
need by developing, testing and marketing hormone replacement therapy (HRT)
products. Because of their ease-of-use and dosing characteristics, drug
developers are continuing to turn to transdermal delivery systems for HRT
products. There are more than 40 million post-menopausal women in the United
States alone, and this group is expected to grow by 50% by 2020. With the
aging of the population worldwide, conditions and diseases such as menopause,
osteoporosis and heart disease, which may benefit from hormone replacement
therapy, are expected to become significantly more prevalent. The industry
continues to attract interest in the form of new participants and products.
While the global market continues to be dominated by the FDA-approved HRT
products of major pharmaceutical firms, regional markets are a bit more
competitive, and present unique challenges to transdermal HRT sector
participants.
Highlights
Analyzes and evaluates the global market opportunity for transdermal
hormone replacement and assesses the probable impact of evolving regulatory,
economic and demand factors
Assesses transdermal products approved or in development for the delivery
of therapeutic hormones
Provides detailed descriptions of hormone replacement treatment segments,
market factors, and business strategies
Forecasts transdermal hormone replacement product demand to 2016 by
geographic region and product segment
Profiles sector companies, their product development activities, supply
chain partners, business strategies, and collaboration partners
Methodology
Research methodology is based on primary research in the form of in-depth
interviews with key market participants, technology developers, distributors,
industry experts, and market influencers, a list that includes regulatory
officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including
trade journal articles, technical literature, industry publications, company
data sheets and published information, and statistical data from government
agencies and trade associations.
Forecasts and projections of market demand and future market activity are
derived using standard modeling and statistical techniques.
About Greystone Associates
Greystone Associates is a medical technology consulting firm focused on the
areas of medical market strategy, product commercialization, venture
development, and market research. We assist medical and healthcare market
participants in achieving their business objectives through the creation of
detailed development strategies, product commercialization programs, and
comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to
provide timely and insightful information and data on focused market segments,
with the aim of providing market participants with the essential knowledge to
refine and execute their marketing plans and financial targets.
Table of Contents
Table of Contents
Executive Summary
Scope and Definitions
The Hormone Replacement Therapy Market
The Opportunity for Transdermal Hormone Replacement Therapy
The Hormone Replacement Therapy Market Opportunity
Evolution in HRT Guidelines
Regional Factors in HRT Practice
Hormone Replacement Therapy Demand Drivers
Competitive Landscape
Factors Limiting Growth
Transdermal Drug Delivery Dynamics
Transdermal HRT Patches
Patch Designs and Construction
Transdermal Patch Manufacturing and Packaging
The Patch Manufacturing Ecosystem
Patch Economics
Transdermal HRT Gels
Transdermal Formulations
IP and Proprietary Technology
Limitations of Topical Gels & Emulsions
Transdermal HRT Sprays
Transdermal HRT Indications and Markets
Hypoestrogenism
Hypogonadism
Menopause
Vasomotor Symptoms
Vaginal Atrophy
Postmenopausal Osteoporosis
Transdermal HRT Product Assessments and Market Prospects
Approved Transdermal HRT Products
Estradiol
Ascend
Azur
Bayer Healthcare
Graceway
KV Pharm
Mylan
Novartis
Watson Laboratories
Upsher-Smith
Faran SA
Janssen-Cilag
Meda
Shiseido
Solvay
Estradiol Levonorgestrel
Bayer Healthcare,
Estradiol/Norethindrone
Novartis
Testosterone
Abbott Labs
Auxilium
Endo Pharms
Teva
Watson Laboratories
Development-Stage Transdermal HRT Products
Estrogen
Testosterone
Other Hormones
Transdermal Hormone Replacement Market Factors
Regional Regulations
Clinical Trials
Quality and Reliability
Indications Prescribing Guidelines and Off-Label Prescribing
Managed Care and Payor Initiatives
Rx-to-OTC Switching
Market Forecasts
Forecast Methodology
Forecasts by Region
Forecasts by Drug Class
Forecasts by Delivery Form Factor
Market Share Data
Company Profiles
Transdermal Hormone Replacement: Products, Players, Markets and Forecasts published by Greystone Research Associates in June 1, 2012. This report price starts from US $ 3850.
Press Release
Hormone Replacement Therapy Market Attracts Over 40 Million Post-Menopausal Women in U.S.
May 28th, 2012
Global Information Inc. would like to present a new market research report, "Transdermal Hormone Replacement: Products, Players, Markets and Forecasts" by Greystone Research Associates.
The Evolving Landscape for Hormone Replacement
There are more than 40 million post-menopausal women in the United States alone, and this group is expected to grow by 50% by 2020. With the aging of the population worldwide, conditions and diseases such as menopause, osteoporosis and heart disease, which may benefit from hormone replacement therapy, are expected to become significantly more prevalent.
The incidence and associated morbidity of decreasing hormone levels have come to the forefront as a quality-of-life issue for patients and their families. For the past two decades, the healthcare industry has responded to this clinical need by developing, testing and marketing hormone replacement therapy (HRT) products. Because of their ease-of-use and dosing characteristics, drug developers are continuing to turn to transdermal delivery systems for HRT products. The industry continues to attract interest in the form of new participants and products. While the global market continues to be dominated by the FDA-approved HRT products of major pharmaceutical firms, regional markets are a bit more competitive, and present unique challenges to transdermal HRT sector participants.
The new transdermal hormone replacement report by Greystone Research Associates will be released this coming June. The study is designed to provide drug company decision makers, drug developers, device packaging designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for therapeutic hormones administered transdermally. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
About the New Report:
Analyzes and evaluates the global market opportunity for transdermal hormone replacement and assesses the probable impact of evolving regulatory, economic and demand factors
Assesses transdermal products approved or in development for the delivery of therapeutic hormones
Provides detailed descriptions of hormone replacement treatment segments, market factors, and business strategies
Forecasts transdermal hormone replacement product demand to 2016 by geographic region and product segment
Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners